Recursion Pharmaceuticals (RXRX) reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model ...

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Find the latest on short interest, settlement dates, average share volume, and days to cover for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Find annual and quearterly earnings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) including earnings per share, earnings forecasts at Nasdaq.com.